Ventricular Arrhythmia-Free Survival Following Therapeutic Hypothermia in Patients with Sudden Cardiac Death Due to Ventricular Tachycardia or Fibrillation

Medicinal herbs and some derivatives have been used in the treatment of heart disease which is rarely responsible for ventricular arrhythmias and cardiac arrest. Ventricular tachycardia (VT) increases the risk of sudden cardiac death (SCD). However, only a few reports are available about the cardiac ventricular arrhythmia followed by taking herbal medicines. We present two patients (a couple) without a history of heart disease who referred to the hospital with ventricular arrhythmia.

Download Full-text

Sa1706 A Meta-Analysis and Systematic Review of Serious Ventricular Arrhythmia and Sudden Cardiac Death With Domperidone Use

Gastroenterology ◽

10.1016/s0016-5085(16)31235-5 ◽

2016 ◽

Vol 150 (4) ◽

pp. S352

Author(s):

Mohammad Bashashati ◽

Irene Sarosiek ◽

Sharareh Moraveji ◽

Alok Dwivedi ◽

Tariq Siddiqui ◽

...

Keyword(s):

Systematic Review ◽

Sudden Cardiac Death ◽

Ventricular Arrhythmia ◽

Cardiac Death ◽

Meta Analysis

Download Full-text

Antidepressants and Risk of Sudden Cardiac Death: A Network Meta-Analysis and Systematic Review

Medical Sciences ◽

10.3390/medsci9020026 ◽

2021 ◽

Vol 9 (2) ◽

pp. 26

Author(s):

Narut Prasitlumkum ◽

Wisit Cheungpasitporn ◽

Nithi Tokavanich ◽

Kimberly R. Ding ◽

Jakrin Kewcharoen ◽

...

Keyword(s):

Sudden Cardiac Death ◽

Mental Disorders ◽

Ventricular Arrhythmia ◽

Cardiac Death ◽

Selective Serotonin Reuptake Inhibitors ◽

Meta Analysis ◽

Tricyclic Antidepressant ◽

Systemic Review ◽

Analysis Model ◽

Antidepressant Use

Background: Antidepressants are one of the most prescribed medications, particularly for patients with mental disorders. Nevertheless, there are still limited data regarding the risk of ventricular arrhythmia (VA) and sudden cardiac death (SCD) associated with these medications. Thus, we performed systemic review and meta-analysis to characterize the risks of VA and SCD among patients who used common antidepressants. Methods: A literature search for studies that reported risk of ventricular arrhythmias and sudden cardiac death in antidepressant use from MEDLINE, EMBASE, and Cochrane Database from inception through September 2020. A random-effects model network meta-analysis model was used to analyze the relation between antidepressants and VA/SCD. Surface Under Cumulative Ranking Curve (SUCRA) was used to rank the treatment for each outcome. Results: The mean study sample size was 355,158 subjects. Tricyclic antidepressant (TCA) patients were the least likely to develop ventricular arrhythmia events/sudden cardiac deaths at OR 0.24, 0.028–1.2, OR 0.32 (95% CI 0.038–1.6) for serotonin and norepinephrine reuptake inhibitors (SNRI), and OR 0.36 (95% CI 0.043, 1.8) for selective serotonin reuptake inhibitors (SSRI), respectively. According to SUCRA analysis, TCA was on a higher rank compared to SNRI and SSRI considering the risk of VA/SCD. Conclusion: Our network meta-analysis demonstrated the low risk of VA/SCD among patients using antidepressants for SNRI, SSRI and especially, TCA. Despite the relatively lowest VA/SCD in TCA, drug efficacy and other adverse effects should be taken into account in patients with mental disorders.

Download Full-text

Are all non‐sustained ventricular tachycardia the same in hypertrophic cardiomyopathy risk stratification for sudden cardiac death?

Journal of Cardiovascular Electrophysiology ◽

10.1111/jce.14573 ◽

2020 ◽

Vol 31 (8) ◽

pp. 2099-2100

Author(s):

Mohamad Khaled Sabeh ◽

Marwan M. Refaat

Keyword(s):

Ventricular Tachycardia ◽

Hypertrophic Cardiomyopathy ◽

Sudden Cardiac Death ◽

Risk Stratification ◽

Cardiac Death ◽

Sustained Ventricular Tachycardia

Download Full-text

Brugada Syndrome: Fatal Consequences of a Must-Not-Miss Diagnosis

Critical Care Nurse ◽

10.4037/ccn2021499 ◽

2021 ◽

Vol 41 (5) ◽

pp. 15-22

Author(s):

L. Douglas Smith ◽

Sarah Gast ◽

Danielle F. Guy

Keyword(s):

At Risk ◽

Critical Care ◽

Sudden Cardiac Death ◽

Ventricular Arrhythmia ◽

Brugada Syndrome ◽

Cardiac Death ◽

Lifestyle Modification ◽

Genetic Disorder ◽

Cardiac Conduction ◽

St Segment Elevation

Background Brugada syndrome is a genetic disorder of cardiac conduction that predisposes patients to spontaneous ventricular arrhythmia and sudden cardiac death. Although Brugada syndrome is one of the most common causes of sudden cardiac death, patients presenting with the syndrome often go misdiagnosed. This error has potentially fatal consequences for patients, who are at risk for sudden cardiac death without appropriate management. Objective To increase the critical care professional’s knowledge of Brugada syndrome through detailed description of the characteristic electrocardiographic findings, an algorithmic approach to electrocardiogram evaluation, and a case report of a patient with a previously missed diagnosis of Brugada syndrome. The essential concepts of epidemiology, pathophysiology, clinical presentation, risk stratification, and management are reviewed for critical care professionals who may encounter patients with the syndrome. Diagnosis Patients typically present with syncope or cardiac arrest and an abnormal electrocardiographic finding of ST-segment elevation in the precordial leads. The diagnosis of Brugada syndrome centers on identification of its electrocardiographic characteristics by critical care professionals who routinely evaluate electrocardiograms. Critical care professionals, especially nurses and advanced practice nurses, should be proficient in recognizing the electrocardiographic appearance of Brugada syndrome and initiating appropriate management. Interventions Management strategies include prevention of sudden cardiac death through lifestyle modification and placement of an implantable cardioverter-defibrillator. Critical care professionals should be aware of commonly used medications that may exacerbate ventricular arrhythmia and place patients at risk for sudden cardiac death. Conclusion Increased awareness of Brugada syndrome among critical care professionals can decrease patient morbidity and mortality.

Download Full-text

Short Term Variability of Repolarization Predicts Ventricular Tachycardia and Sudden Cardiac Death in Patients with Structural Heart Disease

Heart Rhythm ◽

10.1016/j.hrthm.2010.09.058 ◽

2010 ◽

Vol 7 (11) ◽

pp. 1720-1721

Author(s):

Peter Oosterhoff ◽

Larisa G. Tereshchenko ◽

Marcel A.G. van der Heyden ◽

Raja N. Ghanem ◽

Paul J. De Groot ◽

...

Keyword(s):

Heart Disease ◽

Ventricular Tachycardia ◽

Sudden Cardiac Death ◽

Cardiac Death ◽

Structural Heart Disease ◽

Short Term ◽

Short Term Variability

Download Full-text

Sustained monomorphic ventricular tachycardia: the role of catheter ablation

ESC CardioMed ◽

10.1093/med/9780198784906.003.0539 ◽

2018 ◽

pp. 2279-2288

Author(s):

Tilman Maurer ◽

William G. Stevenson ◽

Karl-Heinz Kuck

Keyword(s):

Heart Disease ◽

Ventricular Tachycardia ◽

Catheter Ablation ◽

Sudden Cardiac Death ◽

Cardiac Death ◽

Therapeutic Option ◽

Structural Heart Disease ◽

Premature Ventricular Contractions ◽

Monomorphic Ventricular Tachycardia ◽

Premature Beats

Monomorphic ventricular tachycardia (VT) may occur in the presence or absence of structural heart disease. The standard therapy for patients with structural heart disease at high risk of sudden cardiac death due to VT is the implantable cardioverter defibrillator (ICD). While ICDs effectively terminate VT and prevent sudden cardiac death, they do not prevent recurrent episodes of VT, since the underlying arrhythmogenic substrate remains unchanged. However, shocks from an ICD increase mortality and impair quality of life. These limitations as well as continuous advancements in technology have made catheter ablation an important treatment strategy for patients with structural heart disease presenting with VT. Idiopathic ventricular arrhythmias include premature ventricular contractions and VT occurring in the absence of overt structural heart disease. In this setting, catheter ablation has evolved as the primary therapeutic option for symptomatic ventricular premature beats and sustained VTs and is curative in most cases. This chapter presents an overview of the principles of invasive diagnosis and treatment of monomorphic VTs in patients with and without structural heart disease and delineates the clinical outcome of catheter ablation. Finally, the chapter provides an outlook to the future, discussing potential directions and upcoming developments in the field of catheter ablation of monomorphic VT.

Download Full-text

Diabetes and arrhythmias

ESC CardioMed ◽

10.1093/med/9780198784906.003.0221 ◽

2018 ◽

pp. 941-944

Author(s):

Heikki Huikuri ◽

Lars Rydén

Keyword(s):

Heart Failure ◽

Ventricular Tachycardia ◽

Sudden Cardiac Death ◽

Vitamin K ◽

Cardiac Death ◽

Vitamin K Antagonists ◽

Left Ventricular ◽

Sustained Ventricular Tachycardia ◽

Patients With Diabetes ◽

Diagnostic Work

Cardiac arrhythmias are more common in subjects with diabetes mellitus (DM) than in their counterparts without diabetes. Atrial fibrillation (AF) is present in 10–20% of the DM patients, but the association between DM and AF is mostly due to co-morbidities of DM patients increasing the vulnerability to AF. When type 2 DM and AF coexist, there is a substantially higher risk of cardiovascular mortality, stroke, and heart failure, which indicates screening of AF in selected patients with DM. Anticoagulant therapy either with vitamin K antagonists or non-vitamin K antagonist oral anticoagulants is recommended for DM patients with either paroxysmal or permanent AF, if not contraindicated. Palpitations, premature ventricular beats, and non-sustained ventricular tachycardia are common in patients with DM. The diagnostic work-up and treatment of these arrhythmias does not differ between the patients with or without DM. The diagnosis and treatment of sustained ventricular tachycardia, either monomorphic or polymorphic ventricular tachycardia, or resuscitated ventricular fibrillation is also similar between the patients with or without DM. The risk of sudden cardiac death is higher in DM patients with or without a diagnosed structural heart disease. Patients with diabetes and a left ventricular ejection fraction less than 30–35% should be treated with a prophylactic implantable cardioverter defibrillator according to current guidelines. Beta-blocking therapy is recommended for DM patients with left ventricular dysfunction or heart failure to prevent sudden cardiac death due to arrhythmia.

Download Full-text

Ventricular tachycardia and sudden cardiac death might complicate the long-term outcome by patients after tetralogy of Fallot repair

Orvosi Hetilap ◽

10.1556/oh.2008.28303 ◽

2008 ◽

Vol 149 (23) ◽

pp. 1067-1069

Author(s):

Attila Mihálcz ◽

Csaba Földesi ◽

Tamás Szili-Török

Keyword(s):

Ventricular Tachycardia ◽

Sudden Cardiac Death ◽

Tetralogy Of Fallot ◽

Cardiac Death ◽

Term Outcome ◽

Long Term Outcome ◽

Cardioverter Defibrillator ◽

Tetralogy Of Fallot Repair

A Fallot-tetralógia miatti műtétet követően a hosszú távú túlélést befolyásoló tényezők közé tartozik a kamrai tachycardia és a hirtelen szívhalál. E betegek gondozásában érdemi segítséget jelent az implantálható cardioverter defibrillátor rendszer. A végleges pacemaker és/vagy implantálható cardioverter defibrillátor implantációját követően ritka, ám potenciálisan letális kimenetelű fertőzéses szövődmény az endocarditis. Ez esetben a leghatékonyabb kezelési mód a kombinált terápia, amely a beültetett készülék + elektródák teljes körű eltávolításából és agresszív antibiotikus kezelésből áll. Célkitűzés: Ilyen esetekben a tervezett reimplantáció különös óvatosságot igényel a nagyobb recidívaarány miatt, amelynek rizikója fokozottabb pacemakerdependencia esetén. Célunk olyan módszer alkalmazása volt, amelynek segítségével a recidíva kockázata minimálisra csökkenthető. Módszer: Esetünkben a korábban Fallot-tetralógia miatt többször műtött, pacemaker-, majd implantálható cardioverter defibrillátor beültetéseken átesett betegnél recidív endocarditis miatt készülék- és elektródaeltávolítást végeztünk, standard antibiotikus terápia alkalmazásával. A reimplantációt minithoracotomián keresztül végeztük. Az így elhelyezett sokkelektróda elégtelen működése miatt egy másik sokkelektródát szubkután vezettünk a hátsó mellkasfali régióba; rendszerünk az indukált kamrafibrillációt sikerrel szüntette meg. Megbeszélés: Esetismertetésünk demonstrálja a szubkután defibrillátorrendszer alkalmazhatóságát és előnyeit speciális körülmények fennállásakor. Felhívjuk a figyelmet arra a tényre, hogy ezt a technikát gyakrabban is lehetne alkalmazni olyan esetekben, amelyekben a transzvénás implantáció nem optimális.

Download Full-text